| Type | Title | Date Released | |
|---|---|---|---|
F-1/A | SHARE RESALE REGISTRATION | Shares: 38,450,000 New | ||
6-K | Evaxion Files Amendment to Registration Statement for EIB Debt Settlement Agreement New | ||
6-K | New phase 2 data highlights strong immune response from Evaxion's personalized cancer vaccine EVX-01 | ||
6-K | Evaxion to present new target validation data for EVX-04 acute myeloid leukemia vaccine at ASH 2026 Meeting | ||
6-K | Evaxion A/S Announces At-The-Market ADS Sales and Resulting Share Capital Increases | ||
6-K | Evaxion to Present Phase 2 EVX-01 Personalized Cancer Vaccine Biomarker Data at SITC 2026 Annual Meeting | ||
6-K | Evaxion Receives International Prix Galien Award for AI-Immunology™ as Best Digital Health Solution | ||
6-K | Evaxion Reports 89% Vaccine Target Precision and Sustained Three-Year T-Cell and Clinical Responses in Phase 2 Trial of Personalized Cancer Vaccine EVX-01 | ||
6-K | Evaxion Reports Sustained Clinical Responses for EVX-01 Personalized Cancer Vaccine at Three-Year Follow-Up in Phase 2 Trial | ||
6-K | Evaxion to Present New Phase 2 Immune Data for Personalized Cancer Vaccine EVX-01 at SITC 2026 | ||
6-K | Evaxion Expands AI-Immunology™ Platform into Autoimmune Diseases | ||
6-K | Evaxion A/S Completes At-the-Market Offering of American Depositary Shares |
